Genetic modification of phages has made significant contributions to cancer diagnostics and therapy in modern research. The development of these molecular tools has enabled a broad spectrum of applications, ranging from vaccine development to biomarker discovery, with significant implications in both medical and biotechnological fields. Among the various phage-based methods, phage display stands out as the most widely used. This technique presents novel concepts with vast potential. In this review, we provide an update on the engineering of M13 bacteriophage and its use in phage display technology in the context of cancer diagnosis and treatment. Additionally, we discuss phage-focused applications that involve the genetic modifications of phages themselves, which contribute to the improvement of cancer biotechnology. The effectiveness of phage display technology in identifying high-affinity ligands for substrates, such as cancer cells and tumor-associated molecules, further enhances its value in biomedical applications.
Get full access to this article
View all access options for this article.
References
1.
SmithGP. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 1985; 228(4705):1315–1317; doi: 10.1126/science.400194
NixonAE, SextonDJ, LadnerRC. Drugs derived from phage display: From candidate identification to clinical practice. MAbs, 2014; 6(1):73–85; doi: 10.4161/mabs.27240
4.
KennedyPJ, OliveiraC, GranjaPL, et al.Monoclonal antibodies: Technologies for early discovery and engineering. Crit Rev Biotechnol, 2018; 38(3):394–408; doi: 10.1080/07388551.2017.1357002
5.
LiC, LiJ, XuY, et al.Application of phage-displayed peptides in tumor imaging diagnosis and targeting therapy. Int J Pept Res Ther, 2021; 27(1):587–595; doi: 10.1007/s10989-020-10108-5
6.
BarderasR, Benito-PeñaE. The 2018 Nobel Prize in Chemistry: Phage display of peptides and antibodies. Anal Bioanal Chem, 2019; 411(12):2475–2479; doi: 10.1007/s00216-019-01714-4
7.
KhondeeS, PiyawattanamethaW. Targeting peptides derived from phage display for clinical imaging. In: Bacteriophages 2019. IntechOpen: UK; 2020, pp. 109–131.
8.
LiuR, LiX, XiaoW, LamKS. Tumor-targeting peptides from combinatorial libraries. Adv Drug Deliv Rev, 2017; 110–111:13–37; doi: 10.1016/J.ADDR.2016.05.009
9.
TeesaluT, SugaharaKN, RuoslahtiE. Mapping of vascular ZIP codes by phage display. Methods Enzymol, 2012; 503:35–56; doi: 10.1016/B978-0-12-396962-0.00002-1
10.
SioudM. Phage display libraries: From binders to targeted drug delivery and human therapeutics. Mol Biotechnol, 2019; 61(4):286–303; doi: 10.1007/s12033-019-00156-8
11.
WanXM, ChenYP, XuWR, et al.Identification of nose-to-brain homing peptide through phage display. Peptides, 2009; 30(2):343–350; doi: 10.1016/j.peptides.2008.09.026
12.
WuCH, LiuIJ, LuRM, et al.Advancement and applications of peptide phage display technology in biomedical science. J Biomed Sci, 2016; 23:8; doi: 10.1186/s12929-016-0223-x
13.
BazanJ, CałkosińskiI, GamianA. Phage display—A powerful technique for immunotherapy: 1. Introduction and potential of therapeutic applications. Hum Vaccin Immunother, 2012; 8(12):1817–1828; doi: 10.4161/hv.21703
14.
IslamMS, FanJ, PanF. The power of phages: Revolutionizing cancer treatment. Front Oncol, 2023; 13:1290296; doi: 10.3389/fonc.2023.1290296
15.
GaoJ, WangY, LiuZ, WangZ. Phage display and its application in vaccine design. Ann Microbiol, 2010; 60(1):13–19; doi: 10.1007/s13213-009-0014-7
16.
WangHY, ChangYC, HuCW, et al.Development of a novel cytokine vehicle using filamentous phage display for colorectal cancer treatment. ACS Synth Biol, 2021; 10(8):2087–2095; doi: 10.1021/acssynbio.1c00266
17.
MarchJB, ClarkJR, JepsonCD. Genetic immunisation against hepatitis B using whole bacteriophage λ particles. Vaccine, 2004; 22(13–14):1666–1671; doi: 10.1016/j.vaccine.2003.10.047
KurzepaA, DabrowskaK, SkaradzińskiG, et al.Bacteriophage interactions with phagocytes and their potential significance in experimental therapy. Clin Exp Med, 2009; 9(2):93–100; doi: 10.1007/s10238-008-0027-8
20.
BlochH. Experimental investigation on the relationships between bacteriophages and Malignant tumors. Arch Virol, 1940; 1(2):481–496.
21.
HoodJD, BednarskiM, FraustoR, et al.Tumor regression by targeted gene delivery to the neovasculature. Science, 2002; 296(5577):2404–2407; doi: 10.1126/science.1070200
22.
GoracciM, PignochinoY, MarchiòS, et al.Phage display-based nanotechnology applications in cancer immunotherapy. Molecules, 2020; 25(4):843; doi: 10.3390/molecules25040843
DavidsonE, DoranzBJ. A high‐throughput shotgun mutagenesis approach to mapping B‐cell antibody epitopes. Immunology, 2014; 143(1):13–20; doi: 10.1111/imm.12323
25.
VernetT, ChoulierL, NominéY, et al.Spot peptide arrays and SPR measurements: Throughput and quantification in antibody selectivity studies. J Mol Recognit, 2015; 28(10):635–644; doi: 10.1002/jmr.2477
26.
AugustinT, CehlarO, SkrabanaR, et al.Unravelling viral camouflage: Approaches to the study and characterization of conformational epitopes. Acta Virol, 2015; 59(2):103–116; doi: 10.4149/av_2015_02_103
27.
FühnerV, HeinePA, ZilkensKJ, et al.Epitope mapping via phage display from single-gene libraries. Human Monoclonal Antibodies: Methods and Protocols. Humana Press: New York, NY; 2019; pp. 353–375; doi: 10.1007/978-1-4939-8958-4_17
28.
Pérez-MartínezD, InfanteYC, RamírezBS, et al.Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology. Sci Rep, 2022; 12(1):12268; doi: 10.1038/s41598-022-16411-z
29.
HeinePA, BallmannR, ThevarajahP, et al.Biomarker Discovery by ORFeome Phage Display. In: Phage Display: Methods and Protocols. Springer: New York, NY; 2023; pp. 543–561. 10.1007/978-1-0716-3381-6_27
30.
SadraeianM, MalekiR, MoraghebiM, et al.Phage display technology in biomarker identification with emphasis on non-cancerous diseases. Molecules, 2024; 29(13):3002; doi: 10.3390/molecules29133002
31.
JakobsenCG, RasmussenN, LaenkholmAV, et al.Phage display–derived human monoclonal antibodies isolated by binding to the surface of live primary breast cancer cells recognize GRP78. Cancer Res, 2007; 67(19):9507–9517; doi: 10.1158/0008-5472.CAN-06-4686
32.
KellyKA, BardeesyN, AnbazhaganR, et al.Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med, 2008; 5(4):e85; doi: 10.1371/journal.pmed.0050085
33.
ReynoldsF, PanneerN, TutinoCM, et al.A functional proteomic method for biomarker discovery. PLoS One, 2011; 6(7):e22471; doi: 10.1371/journal.pone.0022471
34.
CardozoT, CardozoL, BoutjdirM. Autoantibody: Autoantigen competitor decoys: Application to cardiac phenotypes. Front Immunol, 2022; 13:812649; doi: 10.3389/fimmu.2022.812649
35.
PavoniE, VaccaroP, PucciA, et al.Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage. BMC Cancer, 2004; 4:78; doi: 10.1186/1471-2407-4-78
36.
FolkmanJ. Angiogenesis. Annu Rev Med, 2006; 57(1):1–18; doi: 10.1146/annurev.med.57.121304.131306
37.
PasqualiniR, KoivunenE, KainR, et al.Aminopeptidase N is a receptor for tumor-homing peptides and a target for inhibiting angiogenesis. Cancer Res, 2000; 60(3):722–727.
